COAG Stock News & Catalysts

FEATURED

Hemab Therapeutics Initiates SOLARA, a Pivotal Phase 3 Trial of Sutacimig in Glanzmann Thrombasthenia

New

Hemab’s first Phase 3 trial to evaluate once-weekly subcutaneous sutacimig in approximately 75 participants with Glanzmann thrombasthenia Single-arm design with a 24-week run-in followed by 48 weeks of treatment;

Summary

Nov 9, 2026, 7:00 AM ·Globe Newswire

RECENT

Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the 68th ASH Annual Meeting and Exposition

First clinical data for sutacimig in Factor VII deficiency (FVIID) shows multi-fold accumulation of endogenous FVII(a) with shortening of prothrombin time after a single subcutaneous dose in initial participants of the

Nov 4, 2026, 9:05 AM ·Globe Newswire

Hemab Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 10, 2026

CAMBRIDGE, Mass. and COPENHAGEN, Denmark, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics (NASDAQ:COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood

Nov 3, 2026, 7:00 AM ·Globe Newswire

Hemab Therapeutics Strengthens Board of Directors with Appointment of Keli Walbert

CAMBRIDGE, Mass. and COPENHAGEN, Denmark, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics (NASDAQ:COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood

Sep 24, 2026, 4:01 PM ·Globe Newswire

Hemab Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of HMB-003, an Investigational Therapy for the Management of Heavy Menstrual Bleeding

Heavy menstrual bleeding is reported in approximately 1 in 3 reproductive-aged women, according to the American College of Obstetricians and Gynecologists, with approximately 23 million seeking care from a healthcare

Sep 17, 2026, 8:00 AM ·Globe Newswire

The Galien Foundation Announces 2026 Prix Galien USA Nominees for "Best Digital Health Solution," "Best Medical Technology," "Incubators, Accelerators and Equity," and "Best Startup"

Celebrating 20 Years of Honoring the Digital Breakthroughs, Pioneering Startups, and Ecosystems Driving the Future of HealthcareNEW YORK, Aug. 13, 2026 /PRNewswire/ -- The Galien Foundation, the premier global

Aug 13, 2026, 9:00 AM ·PRNewswire

Hemab Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Multiple scientific data presentations, including five oral presentations across three programs, at the International Society on Thrombosis and Haemostasis (ISTH) 2026 Congress in Paris, France New clinical data on

Aug 11, 2026, 7:00 AM ·Globe Newswire

Hemab Therapeutics Presents Clinical and Preclinical Data from Sutacimig in Glanzmann Thrombasthenia and Factor VII Deficiency at the ISTH 2026 Congress

Sutacimig Phase 2 long-term extension (LTE) data show sustained bleed reduction and manageable safety and tolerability; Phase 3 initiation planned 2H 2026 Preclinical data for sutacimig in Factor VII deficiency (FVIID)

Jul 14, 2026, 7:45 AM ·Globe Newswire

Hemab Therapeutics Presents New Clinical Data from HMB-002 in Von Willebrand Disease and Introduces HMB-003 for Heavy Menstrual Bleeding at the ISTH 2026 Congress

HMB-002 clinical data demonstrate proof of mechanism, with dose-dependent, greater than or equal to 2.4-fold peak increases in Von Willebrand Factor (VWF) and Factor VIII (FVIII), normalization of peak thrombin

Jul 12, 2026, 6:28 AM ·Globe Newswire

Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the ISTH 2026 Congress

New results from HMB-002 first-in-human data validate proof of mechanism in Von Willebrand disease (VWD), elevating Von Willebrand Factor (VWF) and Factor VIII (FVIII) levels with subcutaneous dosing; multiple dose

Jun 26, 2026, 9:00 AM ·Globe Newswire

Hemab Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference

CAMBRIDGE, Mass. and COPENHAGEN, Denmark, May 27, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics (NASDAQ:COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation

May 27, 2026, 8:00 AM ·Globe Newswire

Hemab Therapeutics Reports First Quarter 2026 Financial Results

Completed Initial Public Offering in May 2026, raising gross proceeds of $346.7 million and listing on Nasdaq Granted Breakthrough Therapy Designation for sutacimig in Glanzmann thrombasthenia CAMBRIDGE, Mass. and

May 21, 2026, 7:00 AM ·Globe Newswire

Hemab Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

CAMBRIDGE, Mass. and COPENHAGEN, Denmark, May 04, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of

May 4, 2026, 4:01 PM ·Globe Newswire

Hemab Therapeutics Announces Pricing of Upsized Initial Public Offering

CAMBRIDGE, Mass. and COPENHAGEN, Denmark, April 30, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of

Apr 30, 2026, 6:55 PM ·Globe Newswire

Hemab Therapeutics Holdings, Inc. Common Stock COAG · News